119152 | Adenosine A₃ Receptor Antagonist, MRS 1523 - CAS 212329-37-8 - Calbiochem

119152
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Voir les Prix & la Disponibilité
      Click To Print This Page

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical FormulaCAS #
      C₂₃H₂₉NO₃S 212329-37-8

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      119152-5MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients

          Flacon en verre 5 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA pyridine derivative that acts as a highly selective antagonist of A3 receptor with excellent potency in both humans and rodents (Ki = 18.9 nM for human A3R, and 113 nM for rat A3R). Exhibits only a trivial antagonistic activity towards A1 and A2A receptors (Ki = 15.6 µM and 2.05 µM for rat A1R and A2AR, respectively). Abolishes the agonistic effects of Cl-IB-MECA (Cat. No. 119139) on A3R-mediated proliferation of primary human coronary smooth muscle cells. Also, reported to block NECA (Cat. No. 119140)-induced bronchoconstriction in an allergic murine model.
          Catalogue Number119152
          Brand Family Calbiochem®
          Synonyms3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate, MRS 1523, MRS-1523
          References
          ReferencesChen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.
          Product Information
          CAS number 212329-37-8
          FormClear to light brown oil
          Hill FormulaC₂₃H₂₉NO₃S
          Chemical formulaC₂₃H₂₉NO₃S
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetA₃ Receptor
          Primary Target K<sub>i</sub>18.9 nM
          Purity≥95% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Références bibliographiques

          Aperçu de la référence bibliographique
          Chen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-March-2018 JSW
          Synonyms3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate, MRS 1523, MRS-1523
          DescriptionA pyridine derivative that acts as a highly selective antagonist of A3 receptor with excellent potency in both humans and rodents (Ki = 18.9 nM for human A3R, and 113 nM for rat A3R). Exhibits only a trivial antagonistic activity towards A1 and A2A receptors (Ki = 15.6 µM and 2.05 µM for rat A1R and A2AR, respectively). Abolishes the agonistic effects of Cl-IB-MECA (Cat. No. 119139) on A3R-mediated proliferation of primary human coronary smooth muscle cells. Also, reported to block NECA (Cat. No. 119140)-induced bronchoconstriction in an allergic murine model.
          FormClear to light brown oil
          Intert gas (Yes/No) Packaged under inert gas
          CAS number 212329-37-8
          Chemical formulaC₂₃H₂₉NO₃S
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesChen, Z., 2012. FASEB J. 26, 1855.
          Chanyshev, B., et al. 2012. Pharmacol Res.65, 338.
          Choi, I., et al. 2011. Am J Pathol. 179, 2042.
          Fan, M., et al. 2003. Am J Physiol Lung Cell Mol Physiol. 284, L1012.
          Li, A. H., et al. 1998. J Med Chem. 41, 3186.
          Jacobson, K. A., et al. 1999. Drug Dev Res. 45, 113.